Trial record 1 of 2 for:    Deep brain stimulation STN Veterans Affairs
Previous Study | Return to List | Next Study

Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial

This study has been completed.
Sponsor:
Collaborators:
Medtronic
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT01076452
First received: February 24, 2010
Last updated: November 26, 2013
Last verified: November 2013

February 24, 2010
November 26, 2013
April 2002
October 2008   (final data collection date for primary outcome measure)
The Change From Baseline in the UPDRS-III Score at 24 Months With Deep-brain Stimulation and Without Medication. [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]
The primary outcome measure for the comparison of GPi deep brain stimulation (DBS) to STN DBS is the motor function score of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) measured while the patient is off medications and on stimulation at follow-up visits post surgery. UPDRS Part III has 14 items assessing motor skills including facial expression and speech, tremors, rigidity, posture, gait, and bradykinesia. Left and right sides (arms, legs, and hands) are assessed separately for seven of the functions. The motor function (UPDRS part III) assessments are done by turning on the stimulation with and without taking PD medications (on/off) at each in-person visit. A summary score ranging from 0 to 108 is generated by adding the 14 specific motor function responses. The higher score indicates the worse motor function.
Blinded assessment of motor function (Unified Parkinson's Disease Rating Scale (UPDRS) Part III) scores in the on stimulation/off medication condition [ Time Frame: at two years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01076452 on ClinicalTrials.gov Archive Site
  • The Change From Baseline in the UPDRS Scores Part I (Mentation) at 24 Months. [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]
    The UPDRS has four parts (Parts I-IV) in which a total of 42 disease characteristics are assessed. Most characteristics are assessed according to their severity on a 0-4 scale (0 = normal, 4 = most substantial impairment), and some are assessed only for absence (score = 0) or presence (score = 1). Part I has four items assessing intellectual impairment, thought disorder, depression and motivation. A summary score ranging from 0 to16 is generated by adding the four items. The higher score indicates worse condition.
  • The Change From Baseline in the UPDRS Scores Part II (Activity of Daily Living) at 24 Months. [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]
    The UPDRS has four parts (Parts I-IV) in which a total of 42 disease characteristics are assessed. Most characteristics are assessed according to their severity on a 0-4 scale (0 = normal, 4 = most substantial impairment), and some are assessed only for absence (score = 0) or presence (score = 1). Part II has 13 items focusing on activities of daily living including walking, writing, dressing and speech. A summary score ranging from 0 to 52 is generated by adding the 13 items. The higher score indicates worse condition.
  • The Change From Baseline in the UPDRS Scores Part IV (Complication of Therapy) at 24 Months. [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]
    The UPDRS has four parts (Parts I-IV) in which a total of 42 disease characteristics are assessed. Most characteristics are assessed according to their severity on a 0-4 scale (0 = normal, 4 = most substantial impairment), and some are assessed only for absence (score = 0) or presence (score = 1). Part IV includes four categories (11 items) related to dyskinesias, clinical fluctuations of symptoms, and other complications. A summary score ranging from 0 to 23 is generated by adding the four items. The higher score indicates worse condition.
  • Self-reported function [ Time Frame: at two years ] [ Designated as safety issue: No ]
  • UPDRS scores [ Time Frame: at two years ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: at two years ] [ Designated as safety issue: No ]
  • Neurocognitive function [ Time Frame: at two years ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: at two years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial
CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II

The goal of the second phase of the study is to determine if simultaneous bilateral subthalamic nucleus stimulation or simultaneous bilateral globus pallidus stimulation is more effective in reducing symptoms of Parkinson's Disease.

Deep Brain Stimulation (DBS) is a promising therapy for Parkinson's disease (PD) Whether DBS is superior to comprehensive best medical therapy or whether some patients or symptoms respond better to DBS in one area of the brain or the other is currently not known. The goals of this project are to compare the effectiveness of DBS and comprehensive medical therapy as treatments for PD (Phase I) and to compare bilateral DBS at 2 areas of the brain-the subthalamic nucleus (STN) and the globus pallidus (GPi) -to determine the most effective brain site for surgical intervention (Phase II) In this prospective, randomized, multi-center trial, 316 patients will be enrolled at 13 centers over four and a half years. Patients will initially be randomized to immediate surgery (DBS) or to 6 months of "best medical therapy". BMT arm patients will then be randomized to proceed into the DBS surgical phase of the trial. The DBS site (STN pr GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial. Patients will be followed for two years post surgery (24 months for DBS only patients and 30 months for BMT-DBS patients) Effective 8/5/05 randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months. The findings will be critically important in establishing the optimal surgical treatment of the disabling symptoms of PD.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Parkinson's Disease
Device: Bilateral Deep Brain Stimulation
The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
  • Active Comparator: STN
    Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
    Intervention: Device: Bilateral Deep Brain Stimulation
  • Active Comparator: GPi
    Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
    Intervention: Device: Bilateral Deep Brain Stimulation

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
299
April 2009
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • idiopathic Parkinson's Disease
  • Hoehn and Yahr stage 2 or worse when off medications
  • L-dopa responsive with clearly defined "on" periods (i.e. symptoms improve at least partially with L-dopa administration, a characteristic that helps distinguish idiopathic PD from "Parkinson's Plus" and atypical Parkinson's syndromes-see below)
  • persistent disabling symptoms (e.g. on troubling dyskinesias, or disabling "off" periods at least 3 hours/day) despite medication therapy. Patients will have been treated with variable doses of levodopa and dopamine agonists (at a minimum) and will have had an adequate trial of other adjunctive medications)
  • stable on medical therapy for at least one month prior to study enrollment
  • age >21
  • available and willing to be followed-up according to study protocol

Exclusion Criteria:

  • "Parkinson's plus" syndromes, secondary, or atypical Parkinson's syndromes (e.g. progressive supranuclear palsy, striato-nigral degeneration, multiple system atrophy, post-stroke, post-traumatic, or post-encephalitic Parkinson's. These patients have cardinal symptoms characteristic of PD but with additional symptoms indicating other organic brain dysfunction, such as gaze palsies, autonomic dysfunction, lack of response to L-dopa, these individuals tend not to improve with standard treatments for PD)
  • previous Parkinson's Disease surgery
  • medical contraindications to surgery or stimulation (e.g. uncontrolled hypertension, advanced coronary artery disease, other implanted stimulation or electronically-controlled devices including cardiac demand pacemaker, aneurysm clips, cochlear implants, or a spinal cord stimulator) (Note: for the subject who receives either a pacemaker and/or defibrillator after this study enrollment, he/she will be allowed to continue the study if the neurostimulator system can be adequately programmed to permit system compatibility)
  • contraindication to magnetic resonance imaging (e.g. indwelling metal fragments or implants that might be affected by MRI)
  • active alcohol or drug abuse
  • score on Mini-Mental Status examination of 24 or lower, or other neuropsychological dysfunction 9e.g. dementia) that would contraindicate surgery
  • intracranial abnormalities that would contraindicate surgery (e.g. stroke, tumor, vascular abnormality affecting the target area)
  • pregnancy
  • concurrent participation in another research protocol
Both
22 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01076452
468 Phase II, VA-NINDS-01
Yes
Department of Veterans Affairs
Department of Veterans Affairs
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Medtronic
Study Chair: Kenneth Follett VA Medical Center, Iowa City
Department of Veterans Affairs
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP